NURS 660 EXAM 1 FINAL EXAM TEST LATEST
UPDATE WITH 100% SOLVED -GRADED A+
VERIFIED 2025 - 2026 UPDATE
Deutetrabenazine (Austedo) - ANS-VMAT2- inhibitor
-most commonly expected side effects:
-drug interactions:
-potentially serious adverse events:
-FDA indications: Huntington's chorea and TD
-lab work that should be monitored prior to starting and while on the medication:
Haloperidol (Haldol) - ANS--High potency 1st gen, lacks anticholinergic activity
-most commonly expected side effects: high risk for EPS/TD
-drug interactions: d/t high potency ^ risk for TD
-potentially serious adverse events: prolonged QTc risk (IV admin)
-FDA indications: antipscyhotic, reasonable 3rd line p 2 failed SGAs, can augment 2nd
gen @ a low dose
-1st line as PRN for acute agitation (off-label)
-lab work that should be monitored prior to starting and while on the medication:
Lurasidone (Latuda) - ANS--low metabolic risk, must be taken w/ food (350 cal)- QD
dosing
-most commonly expected side effects: low sedation risk
-drug interactions: Tegretol, St. John's Wort (inducers), grapefruit juice (inhibitor)- could
increase dose of med
-potentially serious adverse events: poss ^ risk for EPS than the other 'rones'
-FDA indications:
-lab work that should be monitored prior to starting and while on the medication:
-actually may lower than gain weight, improves Hgb A1c
Lumateperone (Caplyta) - ANS--low metabolic risk, must be taken w/ food
-most commonly expected side effects: sedation
-drug interactions:
-potentially serious adverse events: very low risk for EPS & prolactin elev
-FDA indications: newest antipsychotic, only comes in one dose/ once a day
-lab work that should be monitored prior to starting and while on the medication:
UPDATE WITH 100% SOLVED -GRADED A+
VERIFIED 2025 - 2026 UPDATE
Deutetrabenazine (Austedo) - ANS-VMAT2- inhibitor
-most commonly expected side effects:
-drug interactions:
-potentially serious adverse events:
-FDA indications: Huntington's chorea and TD
-lab work that should be monitored prior to starting and while on the medication:
Haloperidol (Haldol) - ANS--High potency 1st gen, lacks anticholinergic activity
-most commonly expected side effects: high risk for EPS/TD
-drug interactions: d/t high potency ^ risk for TD
-potentially serious adverse events: prolonged QTc risk (IV admin)
-FDA indications: antipscyhotic, reasonable 3rd line p 2 failed SGAs, can augment 2nd
gen @ a low dose
-1st line as PRN for acute agitation (off-label)
-lab work that should be monitored prior to starting and while on the medication:
Lurasidone (Latuda) - ANS--low metabolic risk, must be taken w/ food (350 cal)- QD
dosing
-most commonly expected side effects: low sedation risk
-drug interactions: Tegretol, St. John's Wort (inducers), grapefruit juice (inhibitor)- could
increase dose of med
-potentially serious adverse events: poss ^ risk for EPS than the other 'rones'
-FDA indications:
-lab work that should be monitored prior to starting and while on the medication:
-actually may lower than gain weight, improves Hgb A1c
Lumateperone (Caplyta) - ANS--low metabolic risk, must be taken w/ food
-most commonly expected side effects: sedation
-drug interactions:
-potentially serious adverse events: very low risk for EPS & prolactin elev
-FDA indications: newest antipsychotic, only comes in one dose/ once a day
-lab work that should be monitored prior to starting and while on the medication:
